Nath Bio-Genes (India) Ltd 16 Nov 2026 12:00 AM
Nath Bio-Genes (India) Ltd consolidated sales down 87.59% on year in Q2FY2027, net profit witnessed a sharp fall of 98.70%,
Nath Bio-Genes (India) Ltd`s net profit tanked by 98.70% to Rs 0.42 crore, while revenue from operations nosedived 87.59% to Rs 40.74 crore in Q2FY27 over Q2FY26. The market capitalization of Other Agricultural Products industry group stocks on BSE stood at Rs 59099.65 crore, slipping 2.20%. It has improved by 2.17% over last one week and dipped slightly by 1.87% in last one month while the market capitalization of Nath Bio-Genes (India) Ltd has marginally improved by 2.48% and 7.74% in the same period respectively. Profit before tax (PBT) of Nath Bio-Genes (India) Ltd stood at Rs 1.31 crore in Q2 FY27, crashing by 61.36% year-on-year, and plunging by 96.03% quarter-on-quarter. EBITDA came in at Rs 3 crore, tumbling by 33.01% YoY and tanking 91.58% sequentially. Total expenses tumbled by 87.41% to Rs 37.05 crore in Q2FY27 over Q2FY26. During the quarter, employee benefits expense was at Rs 10.33 crore, dipping slightly 4.53% YoY. For FY26, revenue from operations soared by 21.98% to Rs 445.1 crore, while net profit saw a mild growth of 9.38% to Rs 41.63 crore, compared to previous FY. EBITDA jumped by 4439% to Rs 44.62 crore, and PBT improved 15.63% to Rs 46.3 crore compared to previous FY. The company`s consolidated net cash flow from operating activities stood at Rs 12.57 crore in FY26, as against Rs 17.58 crore in FY25. Nath Bio-Genes (India) Ltd crashed 13.51% in last one year, underperforming the benchmark BSE Sensex which has slipped by 3.42% during the same period.
Nath Bio-Genes (India) Ltd 07 Nov 2026 12:00 AM
Nath Bio-Genes to review financial results at board meeting November 14, 2026,
Nath Bio-Genes (India) Limited will hold a board meeting on Saturday, November 14, 2026, to approve the unaudited financial results for both standalone and consolidated entities for the quarter and half year ended September 30, 2026, in compliance with Regulation 29 and 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015; the company closed its trading window for insider trading prevention from September 30, 2026, and it will reopen on November 17, 2026.
Nath Bio-Genes (India) Ltd 21 Oct 2026 12:00 AM
Nath Bio-Genes submitted a compliance certificate to SEBI, confirmed by Bigshare Services,
Nath Bio-Genes (India) Limited submitted a compliance certificate for the quarter ended September 30, 2026, received from M/s Bigshare Services Pvt. Ltd., its Registrar and Share Transfer Agent, in accordance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, and confirmed by Bigshare Services Pvt. Ltd.
Nath Bio-Genes (India) Ltd 28 Sep 2026 12:00 AM
Nath Bio-Genes closes trading window ahead of financial results declaration,
Nath Bio-Genes (India) Limited informed the BSE Limited and National Stock Exchange of India Ltd. that the trading window for dealing in the company`s securities will be closed from Thursday, October 1, 2026, up to 48 hours after the declaration of unaudited financial results for the quarter and half year ending September 30, 2026, in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company’s Code of Conduct for Prevention of Insider Trading.
Nath Bio-Genes (India) Ltd 05 Sep 2026 12:00 AM
Nath Bio-Genes sets September 11, 2026, as record date for voting and dividend,
Nath Bio-Genes (India) Limited informed the BSE Limited and National Stock Exchange of India Ltd. that the record date for determining eligibility to vote at the company’s 33rd Annual General Meeting, scheduled for September 24, 2026, and for dividend eligibility is Friday, September 11, 2026.
Subscribe for our
newsletter
Open Account Now